特发性炎症性肌病患者报告的身体功能结局
本研究在美国大型特发性炎症性肌病人群中评估美国国立卫生研究院患者报告结局测量信息系统身体功能-20(PROMIS PF-20)的可行性、依从性和心理测量学特性。共纳入120例患者(远程研究队列82例/中心队列38例),结果显示PROMIS PF-20具有良好的重测信度、结构效度和反应性,且远程与中心入组患者的依从性相似。
要点
- PROMIS PF-20在特发性炎症性肌病患者中显示出良好的心理测量学特性,包括信度、效度和反应性。
- PROMIS PF-20评分与除骨骼外整体评估和肌酸激酶外的所有核心组指标显著相关,并与大多数症状及功能和身体活动指标相关。
- 远程研究队列与中心队列在人口学特征和PROMIS PF-20平均评分上相似,依从性和完成率也相似。
核心结论
- PROMIS PF-20在大型肌炎患者队列中显示出良好的心理测量学特性,包括信度、效度和反应性,且本地或远程入组患者的依从性相似。
研究设计与样本
- My PACER是一项多中心前瞻性观察性研究,纳入特发性炎症性肌病患者,通过传统面对面门诊就诊竞争性招募中心队列(CBC),并通过基于智能手机和网络的技术远程招募远程研究队列(TRC)。
- CBC进一步按1:1比例随机分为传统本地亚队列和远程亚队列。
- 共纳入120例特发性炎症性肌病患者(TRC 82例/CBC 38例,平均±标准差年龄55±13.4岁,女性75%,白人81%)。
- 每月收集患者报告结局和其他患者自评数据,持续6个月;临床医生报告结局在基线和6个月时获取。
主要发现
- TRC与CBC在人口学特征和PROMIS PF-20平均评分上相似。
- PROMIS PF-20评分与年龄、性别或种族无关。
- TRC与CBC之间以及亚队列之间,依从性和完成率相似。
- PROMIS PF-20在1个月时显示出强重测信度。
- PROMIS PF-20与除骨骼外整体评估和肌酸激酶外的所有核心组指标显著相关,并与大多数症状及功能和身体活动指标相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is an unmet need to develop patient-reported outcomes measures for idiopathic inflammatory myopathies (IIM). We aimed to investigate the feasibility, compliance and psychometric properties of the National Institutes of Health's Patient-Reported Outcomes Measurement Information System (PROMIS) physical function-20 (PF-20) in a large US IIM population. METHODS: 'Myositis Patient Centered Tele-Research' (My PACER) is a multicentre prospective observational study of IIM patients, competitively recruited through traditional in-person clinic visits [centre-based cohort (CBC)], and remotely using smartphone- and web-based technology [tele-research cohort (TRC)]. The CBC was further randomly divided (1:1 ratio) into a traditional local subcohort and a remote subcohort. Data collected included patient-reported outcomes and other patient self-assessments monthly for 6 months. Clinician-reported outcomes were obtained at baseline and 6 months. RESULTS: A total of 120 IIM patients were enrolled (82 TRC/38 CBC, mean ± s.d. age 55 ± 13.4 years, 75% females, 81% Caucasians), with similar demographics and mean PROMIS PF-20 score between cohorts. The PROMIS PF-20 score was not associated with age, sex or race. The compliance and completion rates were similar between TRC and CBC as well as subcohorts. PROMIS PF-20 showed strong test-retest reliability at 1 month. PROMIS PF-20 was significantly associated with all core set measures except extra-muscular global and creatine kinase, as well as with most symptoms, and function and physical activity measures. PROMIS PF-20 illustrated concordant change with myositis response criteria and patient assessment, with a large effect size. CONCLUSIONS: PROMIS PF-20 demonstrates favourable psychometric properties including reliability, validity and responsiveness in a large cohort of myositis patients, with similar adherence in local or remotely enrolled patients.
引用
- Keret S, Lomanto Silva R, Chandra T, et al. Patient-reported outcome for physical function in idiopathic inflammatory myopathy. Rheumatology (Oxford). 2025. PMID: 38321360. doi:10.1093/rheumatology/keae091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。